Antiviral therapeutics for flavivirus infections
Antiviral therapeutics for flavivirus infections
批准号:
8655139
负责人:
DENNIS E. HRUBY
金额:
$124.6万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2011
资助国家:
美国
项目状态:
已结题
起止时间:
2011-05-03 至 2016-04-30
关键词:
Animal ModelAnimalsAntibody-Dependent EnhancementAntiviral AgentsApplications GrantsBiochemicalBiologicalBiological AssayBiological AvailabilityBiological ProductsCategoriesCell Culture TechniquesCharacteristicsChemicalsChemistryControlled StudyDataDengueDengue Hemorrhagic FeverDengue VirusDevelopmentDiseaseDisease OutbreaksDrug ExposureDrug FormulationsDrug KineticsDrug StabilityDrug or chemical Tissue DistributionDrug resistanceEquilibriumEvaluationExcretory functionFaceFlavivirusFlavivirus InfectionsFundingGeneticGoalsGovernmentHumanIn VitroInfectionInvestigational DrugsInvestigational New Drug ApplicationLeadLibrariesMetabolicMetabolismMolecularMonitorOralOral AdministrationPharmaceutical PreparationsPharmacologyPhysiologyPopulationPredispositionProcessPropertyPublic HealthReadinessRiskSafetySeriesSerotypingStructure-Activity RelationshipTherapeuticToxic effectToxicologyVaccinesVariantViralVirulenceVirusVirus DiseasesVirus ReplicationWorkabsorptionanaloganalytical methodanimal efficacybasebiodefensedisorder preventiondrug candidatedrug metabolismdrug resistant virusdrug synthesisfitnesshigh throughput screeningimprovedinhibitor/antagonistlead seriespathogenpre-clinicalprogramsprotective efficacyscale upsmall moleculevaccine development
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): There is an urgent need for new antivirals for both treatment and control of dengue virus, given that over 50 million people are infected worldwide with dengue every year, including 500,000 cases of the more severe form of the disease, dengue hemorrhagic fever (DHF) and there are no approved vaccines or antiviral drugs available. Vaccine development is promising but faces several significant challenges including the need to balance protection against all four serotypes of the virus equally in order to avoid antibody-dependent enhancement of infection and risk of DHF. An antiviral drug that inhibits viral replication without increasing the risk for ADE would be extremely valuable for public health by providing a means to control outbreaks, as well as to government stockpiles for biodefense preparedness.
The overall goal of the SIGA dengue program is to develop a small molecule therapeutic for the treatment and/or prevention of disease caused by dengue virus.
A sensitive and specific high throughput screening (HTS) assay has been developed to evaluate compounds from the SIGA chemical compound library for inhibitory activity against dengue-2 (DEN-2) virus replication. Hits have been identified that are potent (EC50<5uM) and selective (CC50>25uM), with initial structure activity relationship in several series of related compounds. Quality hits were characterized for spectrum of activity, mechanism of action (MOA), preliminary absorption, distribution, metabolism and excretion (ADME) properties, preliminary biopharmaceutical properties, and tolerability. Based on this characterization two lead series were identified that have an optimal biological profile consistent with development of an anti-dengue drug. In this application chemical analogs of selected quality hits will be synthesized to improve the properties of the compounds leading to the nomination of a preclinical candidate which will enter into IND-enabling toxicology.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Antiviral therapeutics for flavivirus infections
-
批准号:8461110
-
项目类别:
-
资助金额:$115.21万
-
财政年份:2011
-
负责人:DENNIS E. HRUBY
-
依托单位:
Antiviral therapeutics for flavivirus infections
-
批准号:8076148
-
项目类别:
-
资助金额:$144.28万
-
财政年份:2011
-
负责人:DENNIS E. HRUBY
-
依托单位:
Antiviral therapeutics for flavivirus infections
-
批准号:8262150
-
项目类别:
-
资助金额:$126.0万
-
财政年份:2011
-
负责人:DENNIS E. HRUBY
-
依托单位:
Antiviral therapeutics for flavivirus infections
-
批准号:8836475
-
项目类别:
-
资助金额:$119.24万
-
财政年份:2011
-
负责人:DENNIS E. HRUBY
-
依托单位:
Novel small molecule inhibitors of dengue replication
-
批准号:7609216
-
项目类别:
-
资助金额:$40.45万
-
财政年份:2008
-
负责人:DENNIS E. HRUBY
-
依托单位:
Novel small molecule inhibitors of dengue replication
-
批准号:7676164
-
项目类别:
-
资助金额:$55.93万
-
财政年份:2008
-
负责人:DENNIS E. HRUBY
-
依托单位:
Enhancing the immune response to antigens delivered by the bacterial vector, Stre
-
批准号:7273398
-
项目类别:
-
资助金额:$27.4万
-
财政年份:2007
-
负责人:DENNIS E. HRUBY
-
依托单位:
Enhancing the immune response to antigens delivered by the bacterial vector, Stre
-
批准号:7492158
-
项目类别:
-
资助金额:$28.05万
-
财政年份:2007
-
负责人:DENNIS E. HRUBY
-
依托单位:
Bacterial Commensal Vector Delivery/Smallpox Vaccine
-
批准号:7051706
-
项目类别:
-
资助金额:$49.14万
-
财政年份:2006
-
负责人:DENNIS E. HRUBY
-
依托单位:
DEVELOPMENT OF THERAPEUTIC AGENT FOR SELECTED VIRAL DISAESES
-
批准号:7543547
-
项目类别:
-
资助金额:$834.81万
-
财政年份:2006
-
负责人:DENNIS E. HRUBY
-
依托单位:--
Pox Proteomics
-
批准号:6913018
-
项目类别:
-
资助金额:$27.46万
-
财政年份:2005
-
负责人:DENNIS E. HRUBY
-
依托单位:
Pox Proteomics
-
批准号:7087069
-
项目类别:
-
资助金额:$27.01万
-
财政年份:2005
-
负责人:DENNIS E. HRUBY
-
依托单位:
Variola Virus G1L:An Antiviral Drug Target
-
批准号:6903595
-
项目类别:
-
资助金额:$27.52万
-
财政年份:2004
-
负责人:DENNIS E. HRUBY
-
依托单位:
Variola Virus G1L:An Antiviral Drug Target
-
批准号:6747514
-
项目类别:
-
资助金额:$27.56万
-
财政年份:2004
-
负责人:DENNIS E. HRUBY
-
依托单位:
Antiviral Drugs for Category A Arenavirus
-
批准号:6831392
-
项目类别:
-
资助金额:$209.25万
-
财政年份:2003
-
负责人:DENNIS E. HRUBY
-
依托单位:
Antiviral Drugs Against Hemorrhagic Fever Viruses
-
批准号:6916895
-
项目类别:
-
资助金额:$49.58万
-
财政年份:2003
-
负责人:DENNIS E. HRUBY
-
依托单位:
Small Molecule Inhibitors of Smallpox Virus Replication
-
批准号:6916897
-
项目类别:
-
资助金额:$21.47万
-
财政年份:2003
-
负责人:DENNIS E. HRUBY
-
依托单位:
Antiviral Drugs for Category A Arenavirus
-
批准号:6937696
-
项目类别:
-
资助金额:$321.47万
-
财政年份:2003
-
负责人:DENNIS E. HRUBY
-
依托单位:
Small Molecule Inhibitors of Smallpox Virus Replication
-
批准号:6831540
-
项目类别:
-
资助金额:$217.8万
-
财政年份:2003
-
负责人:DENNIS E. HRUBY
-
依托单位:
DEVELOPMENT OF POXVIRUS PROTEINASE INHIBITORS
-
批准号:6216310
-
项目类别:
-
资助金额:$21.14万
-
财政年份:2000
-
负责人:DENNIS E. HRUBY
-
依托单位:
海外基金